Translational Drug Development (TD2)
Brandie Morris is a clinical trial management professional with extensive experience in the pharmaceutical and clinical research industry. Currently serving as a Clinical Trial Manager at Translational Drug Development (TD2) since June 2023, Brandie has previously held positions at Parexel as a Study Manager and at ICON plc as a Project Associate II. Brandie's earlier career includes roles as a Clinical Trials Assistant at both IQVIA and Aerotek, where responsibilities included managing regulatory submissions and study supplies. Additionally, Brandie worked as a Senior Academic Counselor at the University of Phoenix, advising students on professional goal development. Brandie holds a Master of Liberal Arts in Literature from Baker University and a Bachelor of Arts in English from Rockhurst University.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.